Evermay Wealth Management LLC bought a new stake in Bristol-Myers Squibb Co (NYSE:BMY) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 3,789 shares of the biopharmaceutical company’s stock, valued at approximately $232,000.
A number of other hedge funds and other institutional investors also recently bought and sold shares of BMY. Delphi Private Advisors LLC purchased a new stake in Bristol-Myers Squibb during the fourth quarter worth about $108,000. Atlantic Trust LLC purchased a new stake in Bristol-Myers Squibb during the second quarter worth about $111,000. Massey Quick Simon & CO. LLC increased its stake in Bristol-Myers Squibb by 523.5% during the third quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 1,492 shares during the period. NuWave Investment Management LLC purchased a new stake in Bristol-Myers Squibb during the fourth quarter worth about $119,000. Finally, Horan Capital Advisors LLC. purchased a new stake in Bristol-Myers Squibb during the third quarter worth about $122,000. 71.55% of the stock is currently owned by institutional investors.
Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $66.60 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55. Bristol-Myers Squibb Co has a one year low of $51.56 and a one year high of $70.05. The firm has a market cap of $108,158.63, a P/E ratio of 112.88, a P/E/G ratio of 2.03 and a beta of 0.98.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.01. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The firm had revenue of $5.45 billion for the quarter, compared to analyst estimates of $5.35 billion. During the same period in the prior year, the firm earned $0.63 earnings per share. The business’s quarterly revenue was up 3.9% compared to the same quarter last year. analysts predict that Bristol-Myers Squibb Co will post 3.2 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, May 1st. Investors of record on Friday, April 6th will be paid a dividend of $0.40 per share. The ex-dividend date is Thursday, April 5th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.40%. Bristol-Myers Squibb’s payout ratio is 271.19%.
BMY has been the topic of a number of recent research reports. Vetr lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price target on the stock. in a research note on Tuesday, January 16th. Citigroup set a $72.00 price target on shares of Bristol-Myers Squibb and gave the stock a “buy” rating in a research note on Tuesday, December 5th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “sell” rating to a “hold” rating in a research note on Friday, January 19th. Credit Suisse Group set a $62.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research note on Monday, January 22nd. Finally, BMO Capital Markets set a $49.00 price target on shares of Bristol-Myers Squibb and gave the stock a “sell” rating in a research note on Monday, December 11th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have given a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus target price of $66.30.
ILLEGAL ACTIVITY WARNING: “Evermay Wealth Management LLC Buys New Stake in Bristol-Myers Squibb Co (BMY)” was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/03/17/evermay-wealth-management-llc-buys-new-stake-in-bristol-myers-squibb-co-bmy.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.